Not currently recruiting at UCSF

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

a study on Breast Cancer Vaccine HER2

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment.

Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and standard adjuvant therapy). Standard adjuvant chemotherapy will be pembrolizumab or capecitabine.

Adjuvant therapy will be administered in compliance with the NCCN guideline for breast cancer (Version 8, 2021), and IP (AST-301) will be administered 3 times every 3 weeks in the adjuvant treatment period, with a booster administered at 24 weeks (±7 days) post the third dose of IP administration.

Survival follow up will be performed to determine invasive Disease Free survival(iDFS).

Official Title

A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)

Details

Not provided

Keywords

Breast Cancer, HER 2 low (1+ or 2+ and non-amplified by FISH), Breast Neoplasms, Pembrolizumab, Capecitabine, Sargramostim, AST-301(pNGVL3-hICD), rhuGM-CSF, AST-301(pNGVL3-hICD)+Chemotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Has a residual invasive cancer in the breast(non-pCR) after neoadjuvant treatment
  • Has stage I, II, or III disease prior to surgery per American Joint Committee on Cancer (AJCC)
  • HER 2 1+ by IHC or HER2 2+by IHC without gene amplification by ISH, as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • Hormone receptor (ER and PR) negative by ASCO/CAP guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Demonstrates adequate organ function.

You CAN'T join if...

  • Has a history of hypersensitivity or other contraindications to rhGM-CSF
  • Has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ.
  • Is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs
  • Has a history of autoimmune disease or inflammatory disease
  • Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
  • Is pregnant or breastfeeding or expecting to conceive children

Locations

  • Ucsf Helen Diller Family Comprehensive Cancer Center not yet accepting patients
    San Francisco California 94158 United States
  • Scripps Health not yet accepting patients
    La Jolla California 92037-1035 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Aston Sci. Inc.
ID
NCT05163223
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 146 study participants
Last Updated